Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.4 0.79 (3.66%) Market Cap: 1.59 Bil Enterprise Value: 1.33 Bil PE Ratio: 203.64 PB Ratio: 3.67 GF Score: 62/100

Q2 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript

Aug 03, 2022 / 12:30PM GMT
Release Date Price: $10.68 (+7.12%)
Operator

Good morning, and welcome to the Kiniksa Pharmaceuticals Second Quarter 2022 Financial Earnings Conference Call. (Operator Instructions) And finally, I would like to advise all participants that this call is being recorded. Thank you.

I would now like to hand over to Rachel Frank, Head of IR.

Rachel Frank
Kiniksa Pharmaceuticals, Ltd. - Associate Director of IR

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our second quarter 2022 financial results and corporate update. The press release highlighting these results can be found on our website under the Investors & Media section.

As for the agenda, our CEO, Sanj K. Patel, will start with an introduction. Then Eben Tessari, our Chief Operating Officer, will review our global license agreement with Genentech for the right to develop and commercialize vixarelimab, which we announced this morning. Ross Moat, our Chief Commercial Officer, who will provide an update on our ARCALYST commercial execution. And then Mark Ragosa, our Chief Financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot